Titlebook: ;

吹牛者

,Thyroid Autoantibodies in Graves’ Disease, do not necessarily cause) destruction of thyroid follicular cells and hypothyroidism. Less commonly, atrophic thyroiditis can be caused by TSH receptor antibodies that block TSH action (reviewed in 1). Occasionally, in the same patient, the balance may shift from hyperthyroidism to hypothyroidism, and vice versa.

Crohns-disease

T Cells and the Autoimmune Response to the TSH Receptor,dominantly with conformational epitopes on intact antigen (Chapter 4). In contrast, T cells only interact with antigen that has been internalized and degraded into peptides. Peptides (~ 20 amino acids) are presented to T cells within a groove in MHC class II molecules on the surface of the antigen-presenting cell (APC)(Fig.1).

遠(yuǎn)地點(diǎn)

BARB

朝圣者

Thionamide Drug Therapy, TSH receptor autoantibodies. It seems unlikely that therapy to interrupt the underlying process of thyroid autoimmunity will be available any time soon. Therefore, antithyroid drugs will continue to be needed. This chapter reviews their actions, use, side effects, and role in the management of the hyperthyroid patient.

千篇一律

,Management of Graves’ Disease in Children,eated, Graves’ disease is associated with excessive activity, tremor, tachycardia, flushing, palpitations, accelerated linear growth, weight loss, impaired skeletal mineralization, and poor school performance (3–6). Because Graves’ disease only rarely spontaneously resolves within a short period (3–7), treatment of hyperthyroidism is essential.

無(wú)底

Johanna Lisa Degen,Scott Simpsonoutcome of certain diseases appears to be strongly influenced by the type of helper T cells involved. For example in leishmaniasis the development of a response polarized toward Th1 is important for a successful immune defence, but a response polarized toward Th2 is detrimental as demonstrated in an animal model (2).

surmount

pacific

Zusammenfassung und Schlu?folgerungen, despite an extensive diagnostic and therapeutic experience in over 2 million patients of all ages and a demonstrable record of safety and efficacy many aspects of radioiodine therapy remain controversial and continue to generate lively debate concerning its use in the management of Graves’ disease (4,5)(Table 1).

milligram